Open Accessβ-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer
Author(s) -
Annika Eurola,
Ari Ristimäki,
Harri Mustonen,
Anurmi,
Jaana Hagström,
Pentti Kallio,
Kari Alitalo,
Caj Haglund,
Hanna Seppänen
Publication year - 2022
Publication title -
tumor biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1423-0380
pISSN - 1010-4283
DOI - 10.3233/tub-211581
Subject(s) - medicine , hazard ratio , immunohistochemistry , wnt signaling pathway , neoadjuvant therapy , oncology , tumor progression , immunostaining , confidence interval , pancreatic cancer , cancer , colorectal cancer , grading (engineering) , catenin , gastroenterology , signal transduction , biology , breast cancer , ecology , biochemistry
Wnt/β-catenin signaling is a highly conserved signaling pathway that regulates the transcription factor PROX1. The role of β-catenin and PROX1 in pancreatic cancer is ambiguous, as some studies have associated their expression with tumor regression and some with tumor progression.